Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-3 (canceled).

Claim 4. (canceled)

Claim 5. (canceled).

Claim 6. (canceled)

Claim 7. (canceled)

Claim 8. (canceled)

Claims 9-23 (canceled)

Claim 24. (previously amended) An isolated nucleic acid encoding at least one isolated mammalian anti-dual integrin antibody comprising (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:1, 2, and 3; and (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:4, 5, and 6.

Claim 25. (previously amended) An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 24.

Claim 26. (amended) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid vector according to claim 25 [24].

Claim 27. (amended) A host cell according to claim 26, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, P3X63Ag8.653 ~~653~~,

SP2/0, ~~293~~, HeLa, myeloma, or lymphoma cells~~, or any derivative, immortalized or transformed cell thereof~~.

Claim 28. (amended) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid vector according to claim 25 [24] under conditions in vitro[,] or in vivo ~~or in situ~~, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claims 29-101. (canceled).

Claim 102 (previously presented) An isolated nucleic acid encoding a human monoclonal antibody comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

Claim 103. (previously presented). An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 102.

Claim 104. (amended) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid vector according to claim 103 [102].

Claim 105. (amended) A host cell according to claim 104, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, P3X63Ag8.653 ~~653~~, SP2/0, 293, HeLa, myeloma, or lymphoma cells, ~~or any derivative, immortalized or transformed cell thereof~~.

Claim 106. (amended) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid vector according to claim 103 [102] under conditions in vitro[,] or in vivo ~~or in situ~~, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claim 107. (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody completely inhibits M21 cell adhesion to vitronectin.

Claim 108. (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody comprises a human IgG heavy chain and a human kappa light chain.

Claim 109. (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody comprises an IgGl or IgG3 heavy chain.

Claim 110 (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody is an IgG1kappa antibody.